| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
ML-097 acts as a potent activator of multiple members of the Ras-related GTPase family, including Rac1, cell division cycle 42 (Cdc42), Ras, and Rab7. It is characterized as a "pan" activator, indicating its broad activity across this protein family. The compound binds at an allosteric site located between switch regions I and II of the GTPases. Its mechanism of action involves increasing the affinity of these GTPases for guanine nucleotides, which promotes their activation and downstream signaling.
|
|---|---|
| ln Vitro |
The EC50 values of ML-099 are 50.11 nM, 102.32 nM, 109.64 nM, 20.41 nM, 81.28 nM, 151.35 nM, and 93.32 nM, respectively. It also activates cell division cycle 42 activation mutant, cell division cycle 42 wild type, Ras protein wild type, and GTP binding protein (Rab7)[1].
In vitro, ML-097 demonstrates potent activation of various GTPases, with EC50 values reported for its analog ML-099. These values are 50.11 nM for Cdc42 activated mutant, 102.32 nM for Cdc42 wild type, 109.64 nM for Ras protein wild type, 20.41 nM for GTP-binding protein Rab7, 81.28 nM for Rac1 activated mutant, 151.35 nM for Rac1 wild type, and 93.32 nM for Ras activated mutant. Research on Cdc42 activators suggests they may have beneficial effects in solid tumors and could improve craniofacial development when Cdc42 GEF is mutated. Rho GTPases, which are activated by this compound, significantly influence cell proliferation and migration. |
| ln Vivo |
The in vivo activity of ML-097 is inferred from the biological roles of its targets, as direct studies are limited. Rac2 is primarily expressed in immune cells, and mutations in human Rac2 lead to immunodeficiency, suggesting that activating Rac2 or other Rac family members could be beneficial for such diseases. Rac1 is essential for maintaining hair follicle integrity, and its deficiency in the skin of animal models leads to almost complete hair loss. While these observations highlight the potential therapeutic relevance of activating these GTPases, specific in vivo efficacy data for ML-097 itself are not detailed in the available sources.
|
| Enzyme Assay |
Cell-free assays for ML-097 typically involve measuring its ability to increase the affinity of GTPases for guanine nucleotides. These assays use purified recombinant GTPases and radioactively labeled or fluorescently tagged guanine nucleotides (e.g., GTP). The compound's effect on nucleotide exchange is quantified, providing a direct measure of its activating potential. The IC50 or EC50 values for activating various GTPase isoforms are determined from dose-response curves generated in these biochemical assays.
|
| Cell Assay |
Cellular assays for ML-097 assess its ability to activate downstream signaling pathways in living cells. A common approach involves treating cells expressing specific GTPases and then measuring the activation of downstream effectors, such as the phosphorylation of ERK or AKT. Another method is to use reporter gene assays where the activation of a GTPase pathway leads to the expression of a measurable reporter, such as luciferase. The compound's activity is confirmed by its ability to increase signaling in a dose-dependent manner in these cellular systems.
|
| Animal Protocol |
Specific in vivo animal实验 protocols for ML-097 are not described in the available literature. As a research tool, its in vivo effects would typically be evaluated in animal models relevant to the biological functions of its targets, such as models of cancer, immunodeficiency, or hair growth disorders. However, no such protocols or data are currently available in the public domain.
|
| ADME/Pharmacokinetics |
ML-097 (CAS: 743456-83-9) has a molecular formula of C14H11BrO3 and a molecular weight of 307.14. It is a solid powder, typically white to off-white. The compound is soluble in DMSO. For storage, the powder should be kept at -20°C for up to 3 years, and solutions in solvent can be stored at -80°C for 1 year. The compound should be protected from moisture and light.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for ML-097 are not provided in the available sources. As a research compound, it is intended for research use only and is not for human or veterinary use. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
2-[(2-bromophenyl)methoxy]benzoic acid is one of the benzoic acid compounds.
ML-097 (CAS: 743456-83-9) is also known as CID-2160985. It is categorized as a probe compound and a pan-activator of Ras-related GTPases. It activates key signaling proteins including Rac1, Cdc42, Ras, and Rab7. The compound was developed as part of the NIH Molecular Libraries Program. Its chemical name is 2-[(2-bromophenyl)methoxy]benzoic acid, and it has a purity of ≥98%. It is not an approved drug and is strictly for research purposes. |
| Molecular Formula |
C14H11O3BR
|
|---|---|
| Molecular Weight |
307.13934
|
| Exact Mass |
305.989
|
| CAS # |
743456-83-9
|
| PubChem CID |
2160985
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
445.4±25.0 °C at 760 mmHg
|
| Flash Point |
223.2±23.2 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.629
|
| LogP |
3.92
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
282
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IYPKPTAZUPMKGH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H11BrO3/c15-12-7-3-1-5-10(12)9-18-13-8-4-2-6-11(13)14(16)17/h1-8H,9H2,(H,16,17)
|
| Chemical Name |
2-[(2-bromophenyl)methoxy]benzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~325.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2558 mL | 16.2792 mL | 32.5584 mL | |
| 5 mM | 0.6512 mL | 3.2558 mL | 6.5117 mL | |
| 10 mM | 0.3256 mL | 1.6279 mL | 3.2558 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
